PHARMAC and statins--correction is needed.
作者信息
Metcalfe Scott, Moodie Peter
出版信息
N Z Med J. 2007 Mar 2;120(1250):U2453.
PMID:17339908
Abstract
摘要
相似文献
1
PHARMAC and statins--correction is needed.药物与他汀类药物——需要修正。
N Z Med J. 2007 Mar 2;120(1250):U2453.
2
PHARMAC and statins--getting the best population health gains.药物经济学与他汀类药物——实现最佳的群体健康效益。
N Z Med J. 2006 Jul 21;119(1238):U2092.
3
PHARMAC and the statin debacle.药物经济学与他汀类药物的困境
N Z Med J. 2006 Jun 23;119(1236):U2033.
4
Cardiovascular health in New Zealand: areas of concern and targets for improvement in 2008 and beyond.新西兰的心血管健康：2008年及以后值得关注的领域和改进目标。
N Z Med J. 2008 Feb 15;121(1269):5-10.
5
The sorry saga of the statins in New Zealand--pharmacopolitics versus patient care.
N Z Med J. 2003 Mar 14;116(1170):U360.
6
Unhealthy lifestyle, statins and the secondary prevention of cardiovascular disease.
Intern Med J. 2007 Jun;37(6):427-8. doi: 10.1111/j.1445-5994.2007.01379.x.
7
Benefit/risk ratio of statins in primary prevention.他汀类药物在一级预防中的获益/风险比。
Clin Pharmacol Ther. 2008 Mar;83(3):498-500. doi: 10.1038/sj.clpt.6100256. Epub 2007 May 30.
8
Primary prevention with over-the-counter statins: a cautionary tale.非处方他汀类药物的一级预防：一个警示故事。
Clin Pharmacol Ther. 2005 Sep;78(3):218-20. doi: 10.1016/j.clpt.2005.06.001.
9
Response from PHARMAC: difficult choices.
N Z Med J. 2003 Mar 14;116(1170):U361.
10
The public cost of 3 statins for primary prevention of cardiovascular events in 7 Middle East countries: not all of them can afford it.7个中东国家中3种他汀类药物用于心血管事件一级预防的公共成本：并非所有国家都能负担得起。
Int J Cardiol. 2012 Mar 8;155(2):316-8. doi: 10.1016/j.ijcard.2011.12.011. Epub 2012 Jan 2.
Zotero 插件